Molecular Diagnosis of Benign and Malignant Melanocytic Lesions Using Mass Spectrometry Imaging
Erin H Seeley
Protea Biosciences, Inc.
Mass spectrometry imaging (MSI) is an emergent technology for the analysis of clinical samples. Here, we present an application of MSI to the molecular diagnosis of human melanocytic skin lesions. A training set of 25 benign nevi and 25 malignant melanomas were interrogated and used to create a genetic algorithm for classification. This algorithm was then validated in an independent set of lesions (sensitivity 97%, specificity 85%). Ongoing work is looking at the application of the algorithm to melanocytic lesions that fall in the histologic “gray area” as well as identification of the peptides that were part of the classifier.
Presented at MSACL 2016 US